
Immunic Inc (IMUX) Stock Forecast & Price Target
Immunic Inc (IMUX) Analyst Ratings
Bulls say
Immunic is well-positioned for future success due to their recent financing which allows for de-risking of late-stage development and potential commercial infrastructure. The company's differentiated mechanism of action targeting both inflammatory relapse activity and neuroprotection has shown positive results in clinical trials, and the upcoming Phase 3 trials and potential launch could solidify their position in the market. The lack of current treatments addressing PIRA and overall disability accumulation could make vidofludimus calcium a valuable option for patients, further supporting Immunic's potential for growth.
Bears say
Immunic is facing several challenges as a clinical-stage biopharmaceutical company, including weakened investor demand as evidenced by the recent downgrade to Hold and upcoming reverse stock split. Additionally, the company's future commercial viability may be hindered by its dependence on the success of its Phase 3 trials in multiple sclerosis and the dilution of its shares through future capital raises. While the recent financing and leadership changes may strengthen the company's position, these fundamental concerns suggest a negative outlook on Immunic's stock.
This aggregate rating is based on analysts' research of Immunic Inc and is not a guaranteed prediction by Public.com or investment advice.
Immunic Inc (IMUX) Analyst Forecast & Price Prediction
Start investing in Immunic Inc (IMUX)
Order type
Buy in
Order amount
Est. shares
0 shares